AbCellera Biologics Inc. (ABCL) Stock Analysis

Q: What is the ABCL stock price target?

Take-profit $8.27 (+87.7% upside). Prior stop was $4.10.

Q: Is ABCL overvalued or undervalued?

AbCellera Biologics Inc. trades at a P/E of N/A (forward -5.3). TrendMatrix value score: 5.4/10. Overall verdict: Sell.

Q: What do analysts say about ABCL?

14 analysts cover ABCL with a consensus score of 4.1/5. Average price target: $10.

Recovery setup

SellModerate ConfidenceUpdated 2026-05-02

Healthcare · Biotechnology

Sell if holding. Engine safety override at $4.39: Quality below floor (2.1 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 5.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 20%; Below-average business quality.

$4.39+87.7% A.UpsideScore 4.8/10#119 of 158 Biotechnology

Stop $4.10Target $8.27(analyst − 13%)A.R:R 5.8:1

Analyst target$9.50+116.4%6 analysts

$8.27our TP

$4.39price

$9.50mean

$12

Passes 6/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Suitability: aggressive.

Thesis

Rewards

No bull case signals

Risks

Quality below floor (2.1 < 4.0)

Key Metrics

P/E (TTM)—

P/E (Fwd)-5.3

Mkt Cap$1.3B

EV/EBITDA-4.5

Profit Mgn-194.9%

ROE-14.5%

Rev Growth788.2%

Beta0.85

DividendNone

Rating analysts14

Quality Signals

Piotroski F4/9

Options Flow

P/C0.17bullish

IV112%elevated

Max Pain$2-54.4% vs spot

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

2 floor-breakers

Overall = weighted sum of the 10 dimension scores. Fundamentals (Value/Quality/Growth) carry 45%; market signals (Momentum/Sentiment/Insider/Peer) carry 40%; structure (Technical/Risk/Catalyst) carries 15%.

DimensionScoreWeightContribution

Value5.415%0.81

Quality2.115%0.32

Growth5.015%0.75

Momentum4.710%0.47

Sentiment7.710%0.77

Insider Activity6.510%0.65

Peer Rank4.110%0.41

Technical Setup1.45%0.07

Risk Profile4.05%0.20

Catalyst6.45%0.32

Overall (Σ contributions)4.77

Small float-rounding may cause last-digit differences between this sum and the displayed Overall.

Technicals below the gate floor. Component breakdown shows what dragged the score down.static

Support Resistance

0.1

Bollinger

0.6

52w Position

3.5

Clinical-stage biotech: losses expected pre-commercialisation. Quality floor doesn't distinguish R&D investment from operational decay — components above tell the real story.static

Roe

0.0

Roa

0.0

Operating Margin

0.0

Fcf Quality

0.0

Piotroski F

4.4

Current Ratio

5.0

Moat

5.0

Cash-burning: FCF -234% of revenueNo competitive moatQuality concerns

GatesMomentum 4.7<5.5 (soft — BUY_NOW allowed but watch)EARNINGS PROXIMITY 10d<=14d (soft)Momentum 4.7>=4.5A.R:R 5.8 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTSEMI CYCLE PEAK CLEARRecoverySuitability: Aggressive

RSI

71 · Overbought

↑ 20D MA↑ 50D MA↑ 200D MADEATH CROSSSupport $3.22Resistance $4.42

Price Targets

A.Upside+88.4%

A.R:R5.8:1

Position Sizing

ConvictionNone

Suggested %0.5%

Max %1%

RegimeSteady

Risk Alerts

! Quality below floor (2.1 < 4.0)

Earnings

2/4 beats

Next Earnings2026-05-11 (10d)

Verdict History

reverse chrono — latest first

Loading history...

Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.

Frequently Asked Questions

Is ABCL stock a buy right now?

Sell if holding. Engine safety override at $4.39: Quality below floor (2.1 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 5.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 20%; Below-average business quality. Chart setup: Death cross but MACD improving, RSI 71. Prior stop was $4.10. Score 4.8/10, moderate confidence.

What is the ABCL stock price target?

Take-profit target: $8.27 (+87.7% upside). Prior stop was $4.10. Stop-loss: $4.10.

What are the risks of investing in ABCL?

Quality below floor (2.1 < 4.0).

Is ABCL overvalued or undervalued?

AbCellera Biologics Inc. trades at a P/E of N/A (forward -5.3). TrendMatrix value score: 5.4/10. Verdict: Sell.

What do analysts say about ABCL?

14 analysts cover ABCL with a consensus score of 4.1/5. Average price target: $10.

What does AbCellera Biologics Inc. do?AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet...

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.